ZOETIS WKN: A1KBYX ISIN: US98978V1035 Kürzel: ZTS Forum: Aktien Thema: Hauptdiskussion

Ich werde demnächst nachkaufen

Jemand hat mit Insiderwissen schön profitiert: »Two days ago, someone bought $500,000 Zoetis, $ZTS, $160 puts expiring 04/19/2024. Today, the stock dropped at most 10%, due to side effects of its drug being released. They have not exited, yet, but have turned $500,000 into $10 million.«

Denke es bietet sich gerade ein prima Einstieg. Fällt es weiter umso besser, dann wird die Position ausgebaut.

Schwierig die Situation einzuordnen, glaube man sollte wohl erstmal Abstand halten und schauen was dabei herauskommt. Oder wie seht ihr das ?

Hier ein Teil des WSJ-Artikels. Gerne eure Einschätzung dazu: Dr. Leilani Alvarez, senior veterinarian at the Schwarzman Animal Medical Center in New York City, said many dogs that she has given Librela to have improved significantly, while others showed side effects. One dog with a neurological condition lost energy and was less eager to move, while another couldn’t walk. Both dogs improved after stopping injections. She reported the events to Zoetis. Meanwhile, Alvarez said she wouldn’t give Librela to dogs with conditions like neurological issues, cancer, immune diseases or kidney problems.  Dr. Duncan Lascelles, a professor of translational pain research and management at North Carolina State University’s College of Veterinary Medicine who helped Zoetis design Solensia studies, recommends prescribing the drug to dogs matching the criteria used in the trial. The trials didn’t include dogs with neurological conditions or lameness unrelated to osteoarthritis. “Sometimes with the latest thing that’s new and shiny everyone wants it to be this perfect therapeutic in all situations. That’s just not going to happen,” Lascelles said. “I don’t know what cases they’re not right for. That’s something we learn over time.”